OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging

Ferumoxytol is an iron-based substance that has been primarily used to treat anemia. Research into a novel use of the substance — to improve imaging of tumors — began in an Oregon Health & Science University laboratory nearly 30 years ago, with efforts led by Edward Neuwelt, M.D., a professor and lead researcher in OHSU’s Department of Neurology and founder of OHSU’s Neuro-Oncology Blood-Brain Barrier Program.

Now, the successful completion of the decades-long project means a new tool to battle brain cancer. Physicians can use this new imaging option to see an additional, multidimensional view of the cancerous area in the brain. Read more at the OHSU News story.